Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy HOOKIPA Pharma stock

Own HOOKIPA Pharma stock in just a few minutes.

HOOKIPA Pharma Inc is a biotechnology business based in the US. HOOKIPA Pharma shares (HOOK) are listed on the NASDAQ and all prices are listed in US Dollars. HOOKIPA Pharma employs 109 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in HOOKIPA Pharma

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – HOOK – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

HOOKIPA Pharma share price

Use our graph to track the performance of HOOK stocks over time.

HOOKIPA Pharma shares at a glance

Information last updated 2021-04-29.
52-week range$7.66 - $15.50
50-day moving average $12.95
200-day moving average $11.70
Wall St. target price$22.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-4.91

Buy HOOKIPA Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy HOOKIPA Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

HOOKIPA Pharma financials

Revenue TTM $19.6 million
Gross profit TTM $-35,203,000
Return on assets TTM -20.09%
Return on equity TTM -32.17%
Profit margin -225.09%
Book value $5.25
Market capitalisation $360.9 million

TTM: trailing 12 months

Shorting HOOKIPA Pharma shares

There are currently 1.4 million HOOKIPA Pharma shares held short by investors – that's known as HOOKIPA Pharma's "short interest". This figure is 0.6% up from 1.4 million last month.

There are a few different ways that this level of interest in shorting HOOKIPA Pharma shares can be evaluated.

HOOKIPA Pharma's "short interest ratio" (SIR)

HOOKIPA Pharma's "short interest ratio" (SIR) is the quantity of HOOKIPA Pharma shares currently shorted divided by the average quantity of HOOKIPA Pharma shares traded daily (recently around 250804.76190476). HOOKIPA Pharma's SIR currently stands at 5.46. In other words for every 100,000 HOOKIPA Pharma shares traded daily on the market, roughly 5460 shares are currently held short.

However HOOKIPA Pharma's short interest can also be evaluated against the total number of HOOKIPA Pharma shares, or, against the total number of tradable HOOKIPA Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case HOOKIPA Pharma's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 HOOKIPA Pharma shares in existence, roughly 50 shares are currently held short) or 0.061% of the tradable shares (for every 100,000 tradable HOOKIPA Pharma shares, roughly 61 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against HOOKIPA Pharma.

Find out more about how you can short HOOKIPA Pharma stock.

HOOKIPA Pharma share dividends

We're not expecting HOOKIPA Pharma to pay a dividend over the next 12 months.

HOOKIPA Pharma share price volatility

Over the last 12 months, HOOKIPA Pharma's shares have ranged in value from as little as $7.6572 up to $15.5. A popular way to gauge a stock's volatility is its "beta".

HOOK.US volatility(beta: 1.23)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while HOOKIPA Pharma's is 1.2304. This would suggest that HOOKIPA Pharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

HOOKIPA Pharma overview

HOOKIPA Pharma Inc. , a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site